A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic Pontine Glioma Linked to TP53 Alterations By Ogkologos - May 12, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BIOMEDE study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children July 13, 2018 The Late Alex Trebek’s Wardrobe Is Being Given to Homeless Men... February 25, 2021 FDA Approves Belzutifan for Advanced Renal Cell Carcinoma January 19, 2024 Cancer in My Community: Caring for the Whole Patient in Brazil December 7, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Sugemalimab A Novel Model Helps Better Predict Risk of Cancer Development in... Managing Cancer Pain: Are Better Approaches on the Horizon? Coronavirus Vaccines and People with Cancer: A Q&A with Dr. Steven...
